ARTICLE | Clinical News
Saphris asenapine regulatory update
January 19, 2009 8:00 AM UTC
Schering-Plough received a complete response letter from FDA for an NDA for Saphris asenapine for the acute treatment of schizophrenia in adults and as monotherapy for the acute treatment of manic or ...